Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Estrogen Treatment in Acromegalic Women

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00315107
Recruitment Status : Unknown
Verified May 2006 by Université de Montréal.
Recruitment status was:  Recruiting
First Posted : April 17, 2006
Last Update Posted : May 26, 2006
Information provided by:
Université de Montréal

Brief Summary:
Oral estrogens may be an effective adjuvant treatment for control of acromegaly in patients with resistance to somatostatin analogs.

Condition or disease Intervention/treatment Phase
Acromegaly Drug: Alesse Phase 2

Detailed Description:
This will be a canadian multicenter study with a randomized, double-blind, placebo-controlled design, to assess the efficacy and safety of adjuvant alesse in female acromegalic patients with suboptimal response to sandostatin LAR treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Study Start Date : May 2006
Study Completion Date : August 2007

Resource links provided by the National Library of Medicine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Women 18 years and older treated with somatostatin analogs
  • Active acromegaly

Exclusion Criteria:

  • Cardiovascular or cerebrovascular disease
  • Thrombophlebitis or thromboembolism
  • Breast cancer
  • Non-controlled arterial hypertension
  • Smoking
  • Pregnancy or lactation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00315107

Layout table for location contacts
Contact: Omar SERRI, MD 514-890-8000 ext 25607

Layout table for location information
Canada, Quebec
CHUM - Notre-Dame Hospital Recruiting
Montreal, Quebec, Canada, H2L 4M1
Principal Investigator: Omar Serri, MD         
Sponsors and Collaborators
Université de Montréal
Layout table for investigator information
Principal Investigator: Omar Serri, MD CHUM- Endocrinology

Layout table for additonal information Identifier: NCT00315107    
Other Study ID Numbers: HND01
First Posted: April 17, 2006    Key Record Dates
Last Update Posted: May 26, 2006
Last Verified: May 2006
Additional relevant MeSH terms:
Layout table for MeSH terms
Bone Diseases, Endocrine
Bone Diseases
Musculoskeletal Diseases
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases